Hydroxyurea (Droxia or Siklos), a low-cost therapy with proven efficacy, is considered the most feasible disease-modifying treatment for SCD in LMICs. It has demonstrated significant benefits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback